ArticleInfectious diseases and therapy2024

Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United States.

Zinan Yi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.